Hanmi Pharmaceutical said on the 21st that it signed a supply deal for three combination drugs with U.S. healthcare corporations Organon to export to the Malaysia and Philippines markets. The contract is worth 52.7 billion won.
Under the deal, Hanmi Pharmaceutical will supply combination therapies in cardiovascular and respiratory care, and Organon will handle local marketing, distribution and sales.
In the Philippines, approvals for two items have been completed. The remaining item is expected to be eligible for export after local approval procedures in the Philippines and Malaysia are finalized.
The two companies plan to sequentially pursue local approvals and product launches, then expand the scope of collaboration.
Organon is a global healthcare corporations established in 2021, with a portfolio of more than 70 products. It supplies medicines and medical devices in about 140 markets worldwide, including Southeast Asia.
Hanmi Pharmaceutical said the deal is a strategic partnership to strengthen its push into Southeast Asia, based on its experience collaborating with global drugmakers. In Southeast Asia, demand for medicines is rising quickly due to population growth and a higher prevalence of chronic diseases, and demand for combination therapies to treat chronic conditions such as hypertension is also increasing.
Mazen Altaruti, head of emerging markets at Organon, said, "This collaboration aims to broaden treatment options and improve access to care for patients in Malaysia and the Philippines."
Hwang Sang-yeon, CEO of Hanmi Pharmaceutical, said, "We will accelerate global expansion based on our diverse portfolio of combination therapies," and added, "Through cooperation with Organon, we will improve treatment access for patients in Southeast Asia."